跳至主要内容
临床试验/NCT00735020
NCT00735020已完成1 期

A Phase I, Observer-Blind, Randomized, Single-Center Study to Evaluate Safety, Tolerability and Immunogenicity of a Bedside Mixing Combination of Two Adjuvanted Influenza Vaccines in Healthy Adults Aged 18 to 39 Years.

Novartis Vaccines2 个研究点 分布在 1 个国家目标入组 72 人开始时间: 2008年6月最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
72
试验地点
2
主要终点
Safety as measured through local and systemic reactions and efficacy (immunogenicity) as measured by antibody titers.

研究概览

简要总结

This trial is designed to evaluate safety, tolerability and immunogenicity of a bedside mixing formulation of adjuvanted influenza vaccines.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 39 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy 18 to 39 year old males and females who are in good health and have provided informed consent prior to enrollment

排除标准

  • serious medical conditions
  • allergies to vaccine components, including but not limited to egg/chicken products
  • reduced immune function
  • recent use of immunosuppressive therapy
  • recent use of influenza vaccine

结局指标

主要结局

Safety as measured through local and systemic reactions and efficacy (immunogenicity) as measured by antibody titers.

时间窗: 36 Days

次要结局

  • To evaluate immunogenicity of a single IM injection of adjuvanted Influenza vaccine(36 Days)

研究者

发起方
Novartis Vaccines
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验